MDGN 201

Drug Profile

MDGN 201

Alternative Names: Epodure™; Erythropoietin gene therapy - Aevi Genomic Medicine; MDGN 201 TARGTepo secreting EPO; MDGN-201; TARGTEPO

Latest Information Update: 24 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medgenics
  • Developer Aevi Genomic Medicine
  • Class Antianaemics; Erythropoietins; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaemia
  • Preclinical Beta-thalassaemia; Myelodysplastic syndromes

Most Recent Events

  • 20 Mar 2017 Medgenics completes a phase I/II trial in Anaemia (In dialysis patients) in Israel (NCT02117427)
  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 01 Sep 2016 Medgenics terminates a phase II trial in Anaemia in USA (NCT02468414)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top